BREAKWATER: PFS & OS results of encorafenib, cetuximab & mFOLFOX6 in mCRC
Автор: VJOncology
Загружено: 2025-06-11
Просмотров: 231
Описание:
Scott Kopetz, MD, PhD, FASCO, The University of Texas MD Anderson Cancer Center, Houston, TX, comments on progression-free survival (PFS) and updated overall survival (OS) findings from the BREAKWATER trial (NCT04607421) of encorafenib plus cetuximab with or without mFOLFOX6 in previously untreated BRAF V600E-mutant metastatic colorectal cancer (mCRC). The triplet regimen significantly improved progression-free and overall survival, with a manageable safety profile. These findings support encorafenib plus cetuximab and mFOLFOX6 as a potential new standard of care in this population. This interview took place during the 2025 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
